Bardor Muriel, Nguyen Dzung H, Diaz Sandra, Varki Ajit
Glycobiology Research and Training Center, Department of Medicine, University of California San Diego, La Jolla, California, 92093-0687, USA.
J Biol Chem. 2005 Feb 11;280(6):4228-37. doi: 10.1074/jbc.M412040200. Epub 2004 Nov 22.
N-Glycolylneuraminic acid (Neu5Gc) is a widely expressed sialic acid in mammalian cells. Although humans are genetically deficient in producing Neu5Gc, small amounts are present in human cells in vivo. A dietary origin was suggested by human volunteer studies and by observing that free Neu5Gc is metabolically incorporated into cultured human carcinoma cells by unknown mechanisms. We now show that free Neu5Gc uptake also occurs in other human and mammalian cells. Inhibitors of certain non-clathrin-mediated endocytic pathways reduce Neu5Gc accumulation. Studies with human mutant cells show that the lysosomal sialic acid transporter is required for metabolic incorporation of free Neu5Gc. Incorporation of glycosidically bound Neu5Gc from exogenous glycoconjugates (relevant to human gut epithelial exposure to dietary Neu5Gc) requires the transporter as well as the lysosomal sialidase, which presumably acts to release free Neu5Gc. Thus, exogenous Neu5Gc reaches lysosomes via pinocytic/endocytic pathways and is exported in free form into the cytosol, becoming available for activation and transfer to glycoconjugates. In contrast, N-glycolylmannosamine (ManNGc) apparently traverses the plasma membrane by passive diffusion and becomes available for conversion to Neu5Gc in the cytosol. This mechanism can also explain the metabolic incorporation of chemically synthesized unnatural sialic acids, as reported by others. Finally, to our knowledge, this is the first example of delivery to the cytosol of an extracellular small molecule that cannot cross the plasma membrane, utilizing fluid pinocytosis and a specific lysosomal transporter. The approach could, thus, potentially be generalized to any small molecule that has a specific lysosomal transporter but not a plasma membrane transporter.
N-羟乙酰神经氨酸(Neu5Gc)是一种在哺乳动物细胞中广泛表达的唾液酸。尽管人类在基因上缺乏合成Neu5Gc的能力,但体内人类细胞中仍存在少量Neu5Gc。人体志愿者研究以及观察到游离的Neu5Gc通过未知机制代谢性地掺入培养的人癌细胞中,提示其来源于饮食。我们现在表明,游离Neu5Gc的摄取也发生在其他人类和哺乳动物细胞中。某些非网格蛋白介导的内吞途径的抑制剂可减少Neu5Gc的积累。对人类突变细胞的研究表明,溶酶体唾液酸转运蛋白是游离Neu5Gc代谢掺入所必需的。从外源性糖缀合物中掺入糖苷结合的Neu5Gc(与人类肠道上皮暴露于饮食中的Neu5Gc相关)既需要转运蛋白,也需要溶酶体唾液酸酶,后者可能作用于释放游离的Neu5Gc。因此,外源性Neu5Gc通过胞饮/内吞途径到达溶酶体,并以游离形式输出到细胞质中,从而可用于激活并转移至糖缀合物。相比之下,N-羟乙酰甘露糖胺(ManNGc)显然通过被动扩散穿过质膜,并在细胞质中可用于转化为Neu5Gc。正如其他人所报道的,这种机制也可以解释化学合成的非天然唾液酸的代谢掺入。最后,据我们所知,这是利用液体胞饮作用和特定的溶酶体转运蛋白将不能穿过质膜的细胞外小分子递送至细胞质的首个例子。因此,该方法有可能推广到任何具有特定溶酶体转运蛋白但没有质膜转运蛋白的小分子。